ClinicalTrials.gg

Program

Pramipexole

Also written as “pramipexole”, “Pramipexole Dihydrochloride” and “Pramipexole Immediate Release”.

Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Tourette Syndrome · Depressive Disorder, Major · Obsessive-Compulsive Disorder, led by 6 companies.

Furthest: phase 4, since Sep 2, 200543 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim360 open or runningphase 4since Sep 2, 2005Aug 22, 2005none ahead
Teva Pharmaceutical Industries30 open or runningphase 4since Nov 10, 2006Nov 10, 2006none ahead
Chase Therapeutics11 open or runningphase 2since Jul 5, 2018Jul 5, 2018none ahead
GlaxoSmithKline10 open or runningphase 1since May 8, 2007May 8, 2007none ahead
Haisco Pharmaceutical Group10 open or runningphase 1since Apr 2, 2026Apr 2, 2026none ahead
Novartis10 open or runningphase 4since Aug 23, 2012Aug 23, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 25 studies since Aug 22, 2005.

  1. Mar 27, 2008Phase 3 study in Restless Legs SyndromeBoehringer Ingelheim · NCT00654498 · 306 enrolled · China
  2. May 19, 2008Phase 3 study in Tourette SyndromeBoehringer Ingelheim · NCT00681863 · 45 enrolled · United States, Germany
  3. May 29, 2008Phase 2 study in FibromyalgiaBoehringer Ingelheim · NCT00689052 · 61 enrolled · United States
  4. Feb 22, 20102 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT01074463, NCT01074450
  5. Aug 30, 2010Phase 3 study in Parkinson DiseaseBoehringer Ingelheim · NCT01191944 · 475 enrolled · China
  6. Oct 1, 2010Phase 1 study in HealthyBoehringer Ingelheim · NCT01214109 · 24 enrolled · China
  7. Aug 23, 2012Novartis's first study: phase 4 study in Parkinson DiseaseNew to NovartisNovartis · NCT01673724 · 121 enrolled · Korea, Republic of
  8. Jun 20, 20142 phase 3 studies in Parkinson DiseaseBoehringer Ingelheim · NCT02172573, NCT02177357
  9. Sep 4, 2014Phase 4 study in Parkinson DiseaseBoehringer Ingelheim · NCT02233023 · 705 enrolled
  10. Oct 9, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02262546, NCT02261103, NCT02264132
  11. Apr 11, 2018Phase 4 study in Parkinson DiseaseBoehringer Ingelheim · NCT03521635 · 98 enrolled · China
  12. Jul 5, 2018Chase Therapeutics's first study: phase 2 study in Depressive Disorder, MajorNew to Chase TherapeuticsChase Therapeutics · NCT03642964 · 24 enrolled · United States
  13. Apr 2, 2026Haisco Pharmaceutical Group's first study: phase 1 study in HealthyNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07519278 · 49 enrolled · China
  14. Jul 22, 2026Phase 1 study in HealthyBoehringer Ingelheim · NCT07727785 · 25 enrolled · Germany

TargetBeta

“D2-like dopamine receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476
rotigotineruleUCBphase 464

Studies

All 43 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07727785Healthy · Germany1CompletedBoehringer IngelheimSep 10, 202625
NCT07519278Healthy · China1CompletedHaisco Pharmaceutical GroupApr 11, 201749
NCT03642964Depressive Disorder, Major · United States2Active, not recruitingChase TherapeuticsDec 30, 202524
NCT03521635Parkinson Disease · China4CompletedBoehringer IngelheimJan 7, 202098
NCT02264132Healthy1CompletedBoehringer IngelheimNov 200624
NCT02262546Healthy1CompletedBoehringer IngelheimOct 200760
NCT02261103Healthy1CompletedBoehringer IngelheimJul 200639
NCT02233023Parkinson Disease4CompletedBoehringer IngelheimJun 2000705
NCT02177357Parkinson Disease3CompletedBoehringer IngelheimJan 2000150
NCT02172573Parkinson Disease3CompletedBoehringer IngelheimJul 2000315
NCT01673724Parkinson Disease · Korea, Republic of4CompletedNovartisMay 23, 2016121
NCT01214109Healthy · China1CompletedBoehringer IngelheimJan 201124
NCT01191944Parkinson Disease · China3CompletedBoehringer IngelheimJan 2012475
NCT01074463Healthy · United States1CompletedTeva Pharmaceutical IndustriesMar 200524
NCT01074450Healthy · United States1CompletedTeva Pharmaceutical IndustriesMar 200524
NCT00689052Fibromyalgia · United States2TerminatedBoehringer IngelheimNov 200861
NCT00681863Tourette Syndrome · United States, Germany3TerminatedBoehringer IngelheimOct 200945
NCT00654498Restless Legs Syndrome · China3CompletedBoehringer IngelheimJun 2009306
NCT00601523Parkinson Disease · United States, Austria, Czech Republic and more3CompletedBoehringer IngelheimJun 2010511
NCT00577460Parkinson Disease · Austria, Czech Republic, Hungary and more3CompletedBoehringer IngelheimJun 2010391
NCT00560508Parkinson Disease · Japan3CompletedBoehringer IngelheimNov 2009112
NCT00558467Tourette Syndrome · United States, Germany2CompletedBoehringer IngelheimJun 200963
NCT00558025Parkinson Disease · France, Germany, Netherlands3CompletedBoehringer IngelheimMay 2008156
NCT00479401Parkinson Disease · United States, Argentina, Austria and more3CompletedBoehringer IngelheimNov 2008539
NCT00472199Restless Legs Syndrome · Austria, Belgium, Finland and more4CompletedBoehringer IngelheimJul 2008331
NCT00471588Obsessive-Compulsive Disorder · United Kingdom1CompletedGlaxoSmithKlineDec 200752
NCT00466167Parkinson Disease · Austria, Czech Republic, Hungary and more3CompletedBoehringer IngelheimNov 2008517
NCT00402233Parkinson Disease · United States4CompletedBoehringer IngelheimSep 2008312
NCT00399477Parkinson Disease4CompletedTeva Pharmaceutical IndustriesJul 2007200
NCT00390689Idiopathic Restless Legs Syndrome · Japan3CompletedBoehringer IngelheimMar 2008154
NCT00375284Restless Legs Syndrome · United States4CompletedBoehringer IngelheimJul 2007404
NCT00356096Restless Legs Syndrome · Finland, France, Germany and more4CompletedBoehringer IngelheimJun 2007404
NCT00349531Restless Legs Syndrome · Denmark, Finland, Germany and more4CompletedBoehringer IngelheimMay 2007369
NCT00321854Parkinson Disease · United States, Austria, Finland and more4CompletedBoehringer IngelheimApr 2009535
NCT00297778Parkinson Disease · Austria, Finland, France and more4CompletedBoehringer IngelheimMay 2008296
NCT00275457Restless Legs Syndrome · Austria, Germany, Netherlands and more3CompletedBoehringer IngelheimApr 2004346
NCT00240409Parkinson Disease · China3CompletedBoehringer IngelheimAug 2004208
NCT00239486Restless Legs Syndrome · Finland2CompletedBoehringer IngelheimApr 2004109
NCT00152997Restless Legs Syndrome · Japan2CompletedBoehringer IngelheimDec 200541
NCT00152958Restless Legs Syndrome · Germany3CompletedBoehringer IngelheimFeb 2005224
NCT00144300Parkinson Disease · United States4CompletedBoehringer IngelheimSep 2010246
NCT00144209Restless Legs Syndrome · Switzerland3CompletedBoehringer IngelheimFeb 200558
NCT00133198Restless Legs Syndrome · United States3CompletedBoehringer IngelheimFeb 2005345

How it is read

Names in the registry

  • “Pramipexole”, 15 entries
  • “pramipexole”, 5 entries
  • “Pramipexole Dihydrochloride”, 4 entries
  • “Pramipexole Immediate Release”, 2 entries
  • “Pramipexole Extended Release”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.